A prospective, randomized, double-blind comparison study of smooth vs. rough stems using cement fixation: minimum 5-year follow-up

2004 ◽  
Vol 19 (2) ◽  
pp. 254
Author(s):  
Vijay Rasquinha ◽  
Chitranjan Ranawat ◽  
Vipul Dua ◽  
Amar Ranawat ◽  
Jose Rodriguez
Keyword(s):  
Comparison Study ◽  
Double Blind ◽  
Blind Comparison

Sulphadiazine/Trimethoprim Once Daily in Maxillary Sinusitis: A Randomized Double-Blind Comparison with Sulphamethoxazole/Trimethoprim B.I.D.

1981 ◽  
Vol 9 (6) ◽  
pp. 478-481 ◽  
Author(s):  
Pierre Federspil ◽  
Peter Bamberg
Keyword(s):  
Maxillary Sinusitis ◽  
Favourable Result ◽  
Double Blind Study ◽  
Double Blind ◽  
Once Daily ◽  
Days Of Therapy ◽  
Significant Difference ◽  
Blind Comparison ◽  
Cure Rates

In a randomized double-blind study fifty-four patients suffering from acute maxillary sinusitis were treated for 10 days with daily doses of sulphadiazine/trimethopim (1 g) and sulphamethoxazole/trimethoprim (1.92 g), respectively. The efficacy was evaluated clinically at two follow-up visits. X-ray investigations were performed at admission and after the therapy. Of thirty-nine patients finally evaluated, thirty-seven showed a favourable result. After 6–8 days of therapy there was significant difference in cure rates in favour of sulphadiazine/trimethoprim (p < 0.05) while the outcome as evaluated after treatment was similar for both drugs.

A Double-Blind Comparison of 0.25% and 0.05% Desoxymethasone, 0.1% Betamethasone Valerate and 1% Hydrocortisone Creams in the Treatment of Eczema

1987 ◽  
Vol 15 (3) ◽  
pp. 160-166 ◽  
Author(s):  
R. E. Ashton ◽  
M. Catterall ◽  
N. Morley ◽  
G. Fairris ◽  
D. N. Joseph
Keyword(s):  
Adverse Effects ◽  
Physical Properties ◽  
Effective Treatment ◽  
The Other ◽  
Betamethasone Valerate ◽  
Clinical Parameters ◽  
Double Blind ◽  
Parallel Group ◽  
Blind Comparison

The efficacy and acceptability of 0.25% and 0.05% desoxymethasone, 0.1% betamethasone valerate and 1% hydrocortisone creams were compared in patients with eczema. A double-blind parallel group multi-centre design was employed in which 96 patients were recruited by four centres. Patients used one cream for a 3-week period and follow-up assessment visits were made at weekly intervals. Efficacy variables were: erythema/redness, scaling, itching and extent of area affected. These variables were assessed by both the investigator and the patient. The 0.25% desoxymethasone was the most effective treatment, producing the greatest degree of improvement in all clinical parameters, hydrocortisone was the least effective and 0.05% desoxymethasone was of intermediate effectiveness. The 0.1% betamethasone produced similar results to 0.25% desoxymethasone for half the assessments; for the other half the results were similar to 0.05% desoxymethasone. No adverse effects were reported during the study. The results are discussed in terms of physical properties of the vehicles and corticosteroid potency.

Ammonium lactate 12% lotion versus a liposome-based moisturizing lotion for plantar xerosis. A double-blind comparison study

1999 ◽  
Vol 89 (10) ◽  
pp. 502-505 ◽  
Author(s):  
JJ Uy ◽  
AM Joyce ◽  
JP Nelson ◽  
B West ◽  
JR Montague
Keyword(s):  
Treatment Effectiveness ◽  
Post Treatment ◽  
Comparison Study ◽  
Double Blind ◽  
Blind Test ◽  
Ammonium Lactate ◽  
Blind Comparison

Two emollients, ammonium lactate 12% lotion and a liposome-based moisturizing lotion, were compared in a double-blind test for efficacy in the treatment of plantar xerosis. A total of 43 out of 57 participants (75%) with bilateral plantar xerosis followed instructions completely and applied the lotions (one to each foot) twice daily for 4 weeks. Each participant was evaluated once a week for 6 weeks (the final 2 weeks for evaluation of post-treatment regression) to determine xerotic grade (degree of dryness) and treatment effectiveness. With both lotions, significant improvement began during the second week of treatment and continued into the fourth week. There were no significant differences between the two lotions in the 6-week patterns of either xerotic grade or treatment effectiveness.

scholarly journals fMRI Neurofeedback-Enhanced Cognitive Reappraisal Training in Depression: A Double-Blind Comparison of Left and Right vlPFC Regulation

2021 ◽  
Vol 12 ◽  
Author(s):  
Micha Keller ◽  
Jana Zweerings ◽  
Martin Klasen ◽  
Mikhail Zvyagintsev ◽  
Jorge Iglesias ◽  
...  
Keyword(s):  
Cognitive Reappraisal ◽  
Symptom Improvement ◽  
Double Blind ◽  
Brain Responses ◽  
Improved Learning ◽  
And Gender ◽  
Blind Comparison ◽  
Left Target ◽  
The Right

Affective disorders are associated with maladaptive emotion regulation strategies. In particular, the left more than the right ventrolateral prefrontal cortex (vlPFC) may insufficiently regulate emotion processing, e.g., in the amygdala. A double-blind cross-over study investigated NF-supported cognitive reappraisal training in major depression (n = 42) and age- and gender-matched controls (n = 39). In a randomized order, participants trained to upregulate either the left or the right vlPFC during cognitive reappraisal of negative images on two separate days. We wanted to confirm regional specific NF effects with improved learning for left compared to right vlPFC (ClinicalTrials.gov NCT03183947). Brain responses and connectivity were studied with respect to training progress, gender, and clinical outcomes in a 4-week follow-up. Increase of vlPFC activity was stronger after NF training from the left- than the right-hemispheric ROI. This regional-specific NF effect during cognitive reappraisal was present across patients with depression and controls and supports a central role of the left vlPFC for cognitive reappraisal. Further, the activity in the left target region was associated with increased use of cognitive reappraisal strategies (r = 0.48). In the 4-week follow-up, 75% of patients with depression reported a successful application of learned strategies in everyday life and 55% a clinically meaningful symptom improvement suggesting clinical usability.

Thylin - follow-up

1964 ◽  
Vol 2 (20) ◽  
pp. 80-80
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Chronic Arthritis ◽  
The Other ◽  
Double Blind ◽  
Previous Therapy ◽  
Blind Comparison

Since we discussed nifenazone (Thylin - West Pharmaceuticals) last April (Drug & Therap. Bull. 2, 26) Hart and Boardman1 have reported a trial of the drug, the first published in Britain. They substituted nifenazone 750–2000 mg daily for phenylbutazone, oxyphenbutazone or salicylates in 26 patients with painful chronic arthritis, mostly rheumatoid. In 18 of these the symptoms became worse; 7 showed some benefit, but less than with the previous therapy, and in one the improvement was comparable with that obtained from phenylbutazone 300 mg daily. Various side effects e.g. dyspepsia, nausea, mouth ulcers, rash occurred in 8 of the 26 patients. In 10 further patients with rheumatoid arthritis a double-blind comparison was made between nifenazone 500 mg three times daily and placebo tablets. Two patients withdrew from the trial; among the other 8, symptoms improved in one, but 7 noted no change. Objective criteria showed no significant improvement. The results of larger trials of the drug, to be published next November, will be awaited with interest.

P.2.061 Long-term weight effects of aripiprazole and olanzapine: Results from a 26-week double-blind comparison study

2004 ◽  
Vol 14 ◽  
pp. S259 ◽  
Author(s):  
W. Carson ◽  
R. McQuade ◽  
N. Abou-Gharbia ◽  
T. Iwamoto ◽  
D. Archibald ◽  
...  
Keyword(s):  
Comparison Study ◽  
Double Blind ◽  
Blind Comparison
Sign in / Sign up

Export Citation Format

Share Document